Biosimilars: Cost Savings, Access, and Safe Integration
Received Date: Aug 01, 2025 / Published Date: Aug 29, 2025
Abstract
Biosimilars are biological medicines demonstrating high similarity to reference products with no clinically meaningful differences in safety, purity, or potency. Their development pathways are designed for efficiency, offering cost savings and improved patient access. Keyconsiderationsincludeanalytical similarity, immunogenicity assessment, and pharmacovigilance. Economicbenefitsand regulatory frameworks, emphasizing a totality of evidence approach, drive adoption. Healthcare professional and patient acceptance, supported by real-world data, are crucial. Interchangeability is vital for market penetration, with evolving scientific and regulatory considerations
Citation: Novak DP (2025) Biosimilars: Cost Savings, Access, and Safe Integration. Int J Res Dev Pharm L Sci 11: 288.
Copyright: 漏 2025 Dr. Peter Novak This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 339
- [From(publication date): 0-0 - Apr 05, 2026]
- Breakdown by view type
- HTML page views: 291
- PDF downloads: 48
